Skip to main content
Hit enter to search or ESC to close
NC Biotech

Utility Menu

  • Why North Carolina
  • Our Community
  • About NCBiotech
Menu

Main navigation

  • Funding
  • Talent & Careers
  • Networking
  • Spaces
  • Resources

Utility Menu

  • Why North Carolina
  • Our Community
  • About NCBiotech
Contact

NCBiotech RTP Headquarters
History of Biotech in NC

About NCBiotech

Who We Are Transforming Life Science Board of Directors

35 Years of Life Science Transformations

Contact Us

Statewide Offices Staff Directory

Images and Logo Gallery

scientists in a lab
NCBiotech Company Directory

Statewide Initiatives

Veterans Outreach Program NC Precision Health Collaborative North Carolina CRO Collaborative

What's Happening

Events Industry News Transformation Talks Podcast

COVID-19 Resources

Funding

Funding

Grants

Research Grants Event & Meeting Grants Proposal Submission Instructions Grant FAQs

Company Funding

Awardee Resources

Past Awards

External Funding

Venture Capital & Angel Investors STEM Funding

Networking

Networking in NCBiotech galleria

Networking Events

Exchange Groups

Services & Sponsorship Opportunities

Company Directory

Resources

Coronavirus CDC
COVID-19 Resources

Entrepreneurs & Startups

Funding

Partnership Opportunities

BATON Referral Network

Core Labs

Company Directory

Life Science Intelligence

Custom Research Market Report Collection Contract Library & Research Services Document Delivery Science Information Consortium

Spaces

Board of Directors room
Reserve a Meeting Space

Conference Center at NCBiotech

Meeting Spaces Make a Reservation Make a Credit Card Payment

Cowork at NCBiotech

NCBiotech Landing Pad

Incubators & Accelerators

Find an Incubator Research Parks

Core Labs

Talent & Careers

Career Seekers

Career & Internship Resources Training Programs NCBiotech Jobs Board Veterans in Life Sciences

Networking

Jobs Network Events Exchange Groups All NCBiotech Events

Employer Resources

Jobs Network Find Talent on NCBiotech Jobs Board Why North Carolina?
Talent and Careers
NCBiotech Jobs Board

Why North Carolina

Industry News

Transformation Talks Podcast

About NCBiotech

Transforming Life Science

Why North Carolina What is Life Science? Transforming North Carolina

Sectors of Attention

Agriculture Bio Defense Biopharma Manufacturing Contract Service Organizations Human Therapeutics Medical Devices Precision Health

Breadcrumb

  1. Home
  2. COVID 19 Resources
COVID-19 Resources

Main navigation

  • Funding
    • Company Funding
    • Research Grants
    • Event Grants
    • Past Awards
    • Awardee Resources
    • External Funding
  • Talent & Careers
  • Networking
  • Spaces
    • Conference Center at NCBiotech
    • Incubators and Accelerators
    • Library
    • NCBiotech Landing Pad
    • Reserve a Conference Facility
  • Resources
    • Life Science Intelligence
    • Company Directory
    • BATON Referral Network
    • Partnership Opportunities
    • Entrepreneur Resources
    • Business Retention Program
    • Core Labs

Utility Menu

  • Why North Carolina
  • Our Community
  • About NCBiotech

Footer Menu

  • About
    • Transforming Life Science
    • Leadership Team
    • Board of Directors
    • Image Gallery
  • Donate
  • News
  • Events
  • Jobs Board

COVID-19 Resources for North Carolina Life Science Companies and Researchers

Given the role North Carolina's life science community are playing in response to the COVID-19 virus, and the effect the outbreak is having on business operations, this page compiles resources and news relevant to local life science companies and researchers.

This page is actively being maintained by Life Science Intelligence at NCBiotech. If you have something to submit, please email research@ncbiotech.org. Follow NCBiotech on Twitter for updates.

Note about products developed in North Carolina: 
Numerous companies and researchers in North Carolina are working on tests and potential vaccines for COVID-19, but NCBiotech doesn’t directly do any scientific research and we do not sell any products. If you are trying to reach one of the other companies mentioned on this page, please contact them directly. If you need help, you might be able to find the company you want to reach in our Company Directory.

Last update: January 15, 2021

Eva Garland Consulting and Grant Engine are both compiling COVID-19 grant funding opportunities; see their pages to sign up for funding alerts.

  • ICODA Grand Challenge
    Deadline: January 19, 2021

    CODA and Grand Challenges are delighted to launch the new pilot Grand Challenges ICODA COVID-19 Data Science grant programme that will focus on addressing major questions about how to reduce the harm of COVID-19 and future pandemics.  The programme aims to unite data and develop processes, analytical tools and infrastructure to achieve rapid scientific progress and impact. The initiative will be a pilot for the ongoing Grand Challenges that seek to develop global collaboration and innovative approaches to major health challenges. Grand Challenges is a family of initiatives, launched by the Bill & Melinda Gates

  • Funding Opportunities Specific to COVID-19 (NIH)
    The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, the NIH wants to assure its recipient community that NIH will be doing its part to help you continue your research.

    Information for NIH applicants and funding recipients is available here.

  • Rapid Acceleration of Diagnostics (RADx) initiative (NIH)
    Deadline: Rolling

    The National Institutes of Health announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) initiative will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing.

    As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19.

    See RADx FAQs here.

  • 2019 Novel Coronavirus Medical Countermeasure Partnership Opportunities (BARDA)
    BARDA is working with its partners to identify promising medical countermeasures and technologies to combat the 2019 novel coronavirus. There are three ways your company or organization can partner with BARDA to fight the ongoing novel coronavirus outbreak.

    BARDA has also created the CoronaWatch Portal seeking information and meeting requests from stakeholders on available medical countermeasures in development. See BARDA's COVID-19 Medical Countermeasure portfolio here.

  • Letter on the COVID-19 (NSF)
    NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, they NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events.

    See other NSF Guidance here.

  • SBIR/STTR Open Topics Addressing COVID-19 
    SBIR/STTR awards relevant to the pandemic can be searched from this link. Current solicitations (as of 12/2/2020) include:

    • HR001119S0019-14: AI-accelerated Biosensor Design (due date: December 31)
    • DHS211-001: Non-Invasive “Breathalyzer” Detection System to Screen for Presence of Viral Respiratory Infections (due date: January 15)
  • Patient-Centered Outcomes Research Institute Funding Opportunities (PCORI)
    Deadline: Rolling

    The Patient-Centered Outcomes Research Institute was created to improve the evidence about what works in health care to better inform real, specific choices faced by patients, clinicians, healthcare administrators and others in the healthcare communities. All open funding opportunities, including COVID-19 related opportunities, are listed here.

  • COVID-19 Therapeutics Accelerator (Gates Foundation)
    The COVID-19 Therapeutics Accelerator is a collaborative effort to research, develop and bring effective treatments to market quickly and accessibly. The COVID-19 Therapeutics Accelerator is prioritizing proposals focused on therapeutics and select accompanying diagnostics. Solutions should have suitability for low-resource settings, with global access through prompt launch and affordability in low- and middle-income countries (LMIC) with a focus on vulnerable populations.


 

  • 21st Century Precision Medicine in the Age of COVID-19
    Host: PMWC
    January 25-27

    Covering critical developments & ongoing activities in COVID while also including the regulatory and investment sides. Speakers include Dr. Anthony Fauci. PMWC's donation to the fight against COVID is this free virtual event.

    The COVID-19 pandemic makes it necessary for leading experts from across disciplines and geographies to come together to jointly address the challenges we are facing when coping with the disruptive nature of the coronavirus SARS-CoV-2 pandemic is having on our healthcare system and our society as a whole. The tasks upon us are enormous and include besides decoding the virus and scaling diagnostics, tackling COVID-19 within existing healthcare systems, building health data platforms that support COVID-19 focused health care, accommodating clinical trials in the era of COVID-19, and developing functional vaccines and therapeutics. The next PMWC 2021 on January 25-27 would be a virtual conference and will touch upon these critical developments and ongoing activities while also including the regulatory and investment sides that influence clinical advancements.

    Register

  • Mayo Clinic COVID-19 Webinar Series
    Host: Mayo Clinic
    Ongoing

    This series of one-hour webinars features Mayo Clinic experts discussing the latest information on COVID-19. 

    Register

  • Clinical Trials in the Era of COVID-19 Weekly Webinar Series
    Host: WCG Clinical
    Ongoing

    The continuing spread of COVID-19 has the industry’s undivided attention, as clinical trial professionals seek the latest perspective on best practices during this unprecedented time. Clinical researchers with ongoing or upcoming clinical trials are working to understand, and ameliorate the impact of this pandemic on studies to keep them on track. Join thousands of peers in these weekly online panels, designed to support healthcare researchers via the industry’s leading voices and perspectives. The panelists share expertise in real-time to inform our collective efforts to discover effective therapies, and minimize the disruption to ongoing and upcoming clinical trials.

    Register

  • Impact of the COVID-19 Pandemic on the Sales of Immunology Drugs
    Host: GlobalData
    January 22, 11:00 a.m.

    The COVID-19 pandemic has been caused by the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world, leading to intense disruption across the healthcare industry in all affected countries. This disruption, coupled with the uncertainty of how immunosuppressive medication will interact with the disease, has led to severe difficulties for patients with immunological disorders seeking treatment, especially as many of these conditions require ongoing immunosuppressive therapy.

    Register

  • SARS-CoV-2 Neutralizing Antibodies for the Treatment of COVID-19
    Host: San Diego American Chemical Society
    February 4, 10:00 p.m.

    Dr. Nirula will discuss the therapeutic landscape of the various neutralizing monoclonal antibodies for COVID-19. Ajay Nirula, M.D., Ph.D. is Vice President, Immunology for Lilly Research Laboratories (LRL) based at the Lilly Biotechnology Center in San Diego. Dr. Nirula joined Lilly in 2015 and is responsible for discovery research and early phase clinical development in immunology. He has most recently served as the medical leader for Lilly’s work during the COVID pandemic that lead to emergency authorization for a therapeutic neutralizing antibody.

    Register

  • North Carolina Companies Responding to the COVID-19 Pandemic
    This list from the NCBiotech Company Directory represents the North Carolina life sciences companies that are contributing to the fight against COVID-19, primarily through the development or manufacturing of diagnostics, therapeutics or vaccines. For more information about how these companies are responding, please see the North Carolina COVID-19 News section at the bottom of this resource guide.

  • Duke

    Duke Margolis Center for Health Policy COVID-19 Response
    Interdisciplinary faculty and researchers from Duke University, Duke Health System and other leading health organizations are collaborating on vital, evidence-based health policy strategies needed now to address the pandemic.

  • UNC Chapel Hill

    COVID-19 Research at UNC-Chapel Hill
    To illustrate the model and expertise Carolina is mobilizing toward COVID-19 and future pandemics, the Campaign for Carolina is highlighting Carolina research projects across five key areas: testing/diagnostics, treatment, prevention/preparation, clinical care research, outcomes and impact research. This list of COVID-19 research is frequently updated with new research projects from schools, units, centers and institutes from across campus.

    UNC COVID-19 Dashboard
    The Coronavirus Dashboard from UNC Gillings School of Global Public Health provides relevant local COVID-19 research to all North Carolinians. Site also includes Coronavirus in NC by the Numbers, including an interactive visualization of coronavirus cases in NC.

    UNC Sheps Center for Health Services Research - COVID-19 Projects
    Sheps researchers are part of an independent, informal collaborative of data scientists, health services and policy researchers, and epidemiologists who are modeling the impact of COVID-19 on North Carolina.

    UNC Research COVID-19 Coverage
    UNC Research is covering the university's research contributions.

  • North Carolina State University

    NC State Experts on COVID-19
    Experts across NC State's campus are available to speak with media about the wide-ranging effects of COVID-19 on our world.

    NC State University Genetic Engineering and Society Center Resources
    Find experts, presentations, and perspectives on the societal and policy dimensions of COVID, biotechnological aspects of testing and vaccination, and food and agricultural policy.

  • Wake Forest

    Wake Forest School of Medicine COVID-19 Research Projects
    Active IRB-approved COVID-19 projects in the Wake Forest School of Medicine network.

  • RTI International COVID-19 Research + Response
    Featuring the latest updates about RTI's COVID-19 research, response, and experts available for interview.

  • University of North Carolina Systemwide Contributions
    Collectively, the University of North Carolina institutions serve North Carolina through instruction, research, and service. The UNC System’s contributions to the state’s efforts to combat this pandemic underscore the long-term value of supporting this mission.

Resources and Initiatives

  • Pipeline Trackers

    • BIO COVID-19 Therapeutic Development Tracker
      BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the Covid-19 pipeline, updated every Monday.
       
    • Milken Institute COVID-19 Treatment and Vaccine Pipeline
      The Milken Institute is tracking the development of potential treatments and vaccines in development for COVID-19.
  • Federal and Global Initiatives and Response

    • Coronavirus (COVID-19) Drug Information from the FDA
      The Center for Drug Evaluation and Research (CDER) is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic, ranging from the acceleration of development for treatments for COVID-19, maintaining and securing drug supply chains, providing guidance to manufacturers, advising developers on how to handle clinical trial issues, and keeping the public informed. Descriptions of efforts led by CDER are linked. 
       
    • Coronavirus Treatment Acceleration Program (CTAP)
      The FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.
       
    • Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership
      The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. 
       
    • Operation Warp Speed
      The Trump administration is prioritizing 14 potential vaccine candidates to undergo further testing, with the goal of having as many as 300 million doses by early 2021.
       
    • Access to COVID-19 Tools (ACT) Accelerator
      The Access to COVID-19 Tools (ACT) Accelerator, is a new, groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. The Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill & Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, the World Bank and Global Financing Facility) to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines.
       
    • COVID Collaborative
      The COVID Collaborative is bringing together many of the nation’s leading experts in public health, education, and the economy together with associations representing state and local leaders and vulnerable communities to take unified action to stop the spread, crush the curve, and safely and sustainably reopen schools, businesses, and other places where Americans gather.

      As part of this effort, the COVID Collaborative is working in partnership with the National Governors Association to develop and support implementation of consensus recommendations on the key elements of a COVID-19 response.

  • COVID-19 Research Tools and Datasets

    • Open-Access Data and Computational Resources to Address COVID-19 (NIH)
      COVID-19 open-access data and computational resources are being provided by federal agencies, including NIH, public consortia, and private entities. These resources are freely available to researchers, and this page will be updated as more information becomes available.

    • COVID-19 Research Database
      The COVID-19 research database is a collection of data sets made freely available to public health and policy researchers to extract insights for combatting the COVID-19 pandemic. The dataset is a pro-bono, cross-industry collaboration. Until now, researchers and policy-makers seeking to answer questions about the pandemic could only do research on fragmented data sets (such as the data set from a particular hospital), or to conduct long, prospective clinical trials, which makes it difficult to rapidly answer questions about the epidemiology and treatment of the disease. The COVID-19 research database is a consortium of institutions pooling their de-identified and limited pandemic-related data to allow researchers to more rapidly conduct studies at a large scale.

    • Pubic Health Genomics and Precision Health COVID-19 Knowledge Base (CDC)
      COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that captures emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.

    • Human Data Science Research Collaborative (IQVIA)
      To accelerate COVID-19 related learning, IQVIA is waiving data access fees for academic researchers to two IQVIA data technology platforms, E360™ and SMART, through October 2020. The intent of this research collaborative is to study the impact of COVID-19 on healthcare systems. Any research directly related to the clinical characteristics of COVID-19, such as treatment options, transmission rates, and/or outcomes, is considered out of scope. Note the number of access opportunities are limited.

    • Coronavirus Research Hub (Elsevier)
      Researchers and data scientists focused on Coronavirus vaccine, drug, clinical and other related research are able to freely access some Elsevier solutions.

    • Coronavirus Method Development Community (Protocols.io)
      Open platform for sharing research methods. This includes the sequencing and detection protocols for coronavirus (for research only, and not for clinical diagnosis). All protocols are fully accessible, citable, and editable. 

    • COVID-19 Open Research Dataset Challenge (CORD-19) (Kaggle)
      The CORD-19 dataset represents the most extensive machine-readable coronavirus literature collection available for data mining to date. This allows the worldwide AI research community the opportunity to apply text and data mining approaches to find answers to questions within, and connect insights across, this content in support of the ongoing COVID-19 response efforts worldwide. 

    • ICODA Workbench
      The International COVID-19 Data Alliance (ICODA) exists to enable and accelerate responsible research.  At its heart is the “Workbench” – a new data platform, provided by our alliance partner Aridhia Informatics that allows researchers to discover, access and analyse global multi-dimensional datasets while respecting confidentiality and privacy. The platform will consolidate data and metadata from federated repositories to allow teams to work collectively on a focused research question. Access to the Workbench is provided free of charge once researchers have been accredited and project proposals approved.

    • CAS COVID-19 Resources (CAS)
      CAS is making a wide range of resources and expertise openly available to support this fight. Resources include:
      • COVID-19 Antiviral Candidate Dataset
      • COVID-19 Protein Target Thesaurus
      • Assay Techniques and test Development for COVID-19 Diagnosis
      • COVID-19 Antiviral Candidate SAR Dataset
      • COVID-19 Bioindicator Explorer

         
    • COVID-19 and Coronavirus Plasmids (Addgene)
      Addgene is a non-profit plasmid repository that facilitates the exchange of genetic material between laboratories. On this page, Addgene is compiling plasmids  containing SARS-CoV-2 sequences and other resources available to industry, academics and nonprofits.
       
    • Disqover COVID-19 (Ontoforce)
      Ontoforce is making available a free COVID-19 dashboard that brings together patents, publications and clinical studies. Linked to these resources are related diseases and health conditions; genes and phenotypes; drugs, chemicals and active substances. Log in is required.
  • AdvaMed National COVID Testing Supply Registry
    To further assist state and federal governments in their pandemic responses, AdvaMed has created a comprehensive, national COVID-19 diagnostic supply registry which compiles information from diagnostic companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. AdvaMed’s registry aims to help streamline communications and data sharing between diagnostic companies and federal and state governments as well as standardize test supply reporting. It also facilitates collaboration with laboratories and other public health stakeholders to optimize access to all platforms of COVID-19 testing so that any potential shortages are identified and addressed quickly.

  • CEPI Survey of global COVID-19 vaccine manufacturing capacity

    Between April 3 and June 19, CEPI – in collaboration with the Bill & Melinda Gates Foundation, The Clinton Health Access Initiative, and PATH – undertook a broad, worldwide, survey of vaccine manufacturers to understand capabilities, capacities and interest in responding to the pandemic. We aimed to assess potential bottlenecks in the vaccine manufacturing and to work out what global capacity might be available to produce billions of doses of vaccine.

    Key findings available here, or see full survey results here.

     

  • COVID Vaccine Facts

    COVID Vaccine Facts is a subsidiary website of the Biotechnology Innovation Organization (BIO). The content on this website serves as an educational tool to link people to third-party scientific and evidenced-based information related to the vaccine development process, along with the safety, efficacy, availability, and affordability of Covid-19 vaccines.

  • The Road to a Vaccine
    Airs at 12:00 P.M. on jnj.com, Facebook, LinkedIn and Twitter.
    This new eight-episode educational video series sponsored by Johnson & Johnson will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine. Each week, host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to bring an end to the deadly pandemic.

 

     

      • Enroll in Clinical Trials and Studies

        • COVID-19 Prevention Network (COVPN)
          COVPN is a unified clinical trial network with the mission to develop and conduct studies to ensure rapid and thorough evaluation of US government-sponsored COVID-19 vaccines and monoclonal antibodies for the prevention of COVID-19 disease. Volunteer here to  take part in COVID-19 prevention clinical trials.
           
        • Clinicaltrials.gov
          Search all clinical studies related to COVID-19.
           
        • Covance (LabCorp) COVID-19 Clinical Trial Connect
          If you have been exposed to or diagnosed with COVID-19, this online screening survey can match you to numerous different COVID-19 research studies or clinical trials near you. Whether it is helping to understand the body’s immune response, taking a short survey of your symptoms, or testing a new vaccine, you can help advance science

        Some local efforts enrolling people in COVID-19 studies include:

        • UNC School of Medicine - Join a Clinical Research Study
          The University of North Carolina at Chapel Hill is actively working to find safe and effective ways to prevent and treat COVID-19. From this page, you're able to access the most updated information regarding clinical research studies that currently open to enrollment.
           
        • UNC Research for Me
          Hosted by the NC TraCS Institute, Research for Me’s COVID-19 projects page lists study opportunities for potential participants. Those who have been diagnosed with COVID-19, are frontline healthcare workers, or wish to help researchers better understand the pandemic’s impact can find a meaningful ways to participate in research happening at UNC and UNC Health.
           
        • Duke COVIDENTIFY
          Duke University doctors and scientists are investigating whether the data from your smartphone and smartwatch can help determine whether or not you have a COVID-19 infection, and how severe the infection is expected to get. You will need to answer two simple questions each day for up to 12 months.
           
        • Duke PROTECT-EHC
          Dr. Anthony Sung and Dr. Paul Wischmeyer at Duke University are looking for people to join their PROTECT-EHC study. Exposed household contacts (EHC) are people who live with someone with COVID-19  and therefore have an increased chance of contracting the virus. We are doing this study is to see if taking a probiotic for 28 days can change the microbiome, or bacteria in the gut and nose. Participation could provide direct benefit as changing the microbiome with our probiotic may reduce symptomatic COVID-19 by 30-50%. 
      • Convalescent Plasma Donation

        Learn more about how convalescent plasma is being used at covidplasma.org, maintained by the American Association of Blood Banks.

        • UNC COVID-19 Plasma Donation
          Have you been diagnosed with COVID-19 and interested in potentially helping others? You may be eligible to donate plasma. We are partnering with the UNC Blood Donation Center in Chapel Hill, NC to schedule plasma collections for eligible donors.
           
        • Convalescent Plasma (Grifols)
          For individuals who have recovered from COVID-19, donating plasma is a great way to make a difference during this exceptional time.   For information about plasma donation opportunities through Grifols in North Carolina, please visit www.grifolsplasma.com/en/endcv19  or call 1-866-END-CV19. Convalescent plasma from donors will be manufactured into a hyper-immune therapy specific to COVID-19 at Grifols’ manufacturing facility in Clayton, NC

      • BIO Coronavirus Hub

        The BIO Coronavirus Hub is the primary life scicence-focused resource to connect companies that have relevant supplies, capacities, and resources to share, with those companies, researchers, or healthcare providers that need them. The new hub will enable users to post requests for urgently needed items, as well as to post the availability of supplies and capacity. Connections for medical supplies will be facilitated in partnership with Healthcare Ready to ensure an organized and optimized allocation of items in need, and thus will not be publicly available or searchable.

      • Med Device Network (AdvaMed)
        The Med Device Network connects organizations to help quickly scale production and distribution of complex medical devices currently in short supply (e.g. ventilators, dialysis machines, pulse oximeters, etc.)

      • PPE and Supply Donations
        The following health care systems have issued calls for supply donations:

        • UNC Health
        • Duke Health

        HealthConnect South is building a directory of healthcare entities requesting donations of supplies, equipment, staff and money.

      • Critical Supply Production Database
        IES/NCMEP is building a database of companies with certain capabilities during this critical time. There are over 20 critical supplies needed to respond to COVID-19. If your company currently does or can quickly begin production, please fill out the information below. NCMEP will share this information with federal and state stakeholders such as the US Department of Commerce and NCDPS Emergency Management agency to help meet these needs. Furthermore, your secured information provides us with crucial analytical data to dynamically generate topics, related companies, and resources. 

      • Duke Health COVID-19 Response Funds
        Donate to Duke's COVID-10 Response funds for research support and care support. 
         

      • UNC COVID-19 Research Accelerator Fund
        Your contribution to the UNC COVID-19 Research Accelerator Fund provides immediate, flexible support to Carolina's critical research teams focused on COVID-19 testing, treatment and prevention.

      • COVID-19 National Scientist Volunteer Form
        This is a database of scientists who are able to volunteer time, expertise, equipment, and consumables to help government entities, non-profits, universities and local organizations respond to the COVID-19 crisis. 

      • MBAs Fight COVID-19
        This initiative from Harvard Business School connects MBA students across the country who can offer their skills to organizations in the public, private and social sectors.

      Many journals and publishers are committing to making coronavirus and COVID-19 research articles free to access.

      • COVID-19 Science Updates (CDC)
        To help inform CDC’s COVID-19 Response, as well as to help CDC staff stay up to date on the latest COVID-19 research, the Response’s Office of the Chief Medical Officer has collaborated with the CDC Office of Library Science to create a series called COVID-19 Science Update. This series, the first of its kind for a CDC emergency response, provides brief summaries of new COVID-19-related studies on many topics, including epidemiology, clinical treatment and management, laboratory science, and modeling. These summaries are released every Tuesday and Friday.

      • LitCovid from the National Library of Medicine
        LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus. It is the most comprehensive resource on the subject, providing a central access to 842 (and growing) peer-review articles.

      • JAMA Coronavirus Disease 2019

      • Elsevier Novel Coronavirus Information Center

      • Springer Nature SARS-CoV-2 and COVID-19

      • The Lancet COVID-19 Resource Centre

      • New England Journal of Medicine Coronavirus

      • Taylor & Francis COVID-19 Content

      • Science (AAAS) Coronavirus: Research, Commentary and News

      • CDC Public Health Genomics and Precision Health Knowledge Base: Coronavirus Disease Portal

      • Disqover COVID-19
        Ontoforce is making available a free COVID-19 dashboard that brings together patents, publications and clinical studies. Linked to these resources are related diseases and health conditions; genes and phenotypes; drugs, chemicals and active substances. Log in is required.

      • Coronavirus Resources in the Carolina Digital Repository
        Contains research, dissertations and papers from the University of North Carolina

      • Meta COVID-19 Feed
        Meta, a research discovery tool that uses machine learning to help researchers keep pace with discoveries through targeted feeds of preprints and papers. Researchers can sign up for a free Meta account to see the full COVID-19 feed.

      • COVID-19 Global Literature on coronavirus disease (WHO)
        WHO is gathering the latest international multilingual scientific findings and knowledge on COVID-19. The global literature cited in the WHO COVID-19 database is updated daily (Monday through Friday) from searches of bibliographic databases, hand searching, and the addition of other expert-referred scientific articles.

      Though many COVID trackers are reporting on similar themes (such as COVID cases and hospitalizations), the difference between how the trackers break down and present the data may suit different personal needs. Below are a sample of some popular COVID trackers.

      Notes about data quality: Inclusion criteria and data cut-off times vary between different sources, which therefore can cause individual COVID trackers to vary depending on which sources they pull from. For example, not all states separately distinguish viral (current infection) and antibody (past infection) tests, or confirmed vs. probable COVID deaths. Some COVID trackers have chosen to exclude county-level data sources due to the variation of such reporting methods, and others make effort to normalize the data so as to include as much up to date data as possible. It is recommended to refer to a chart’s captions and “About the Data” notes to ensure a rich awareness of what the data include/do not include.

      • COVID-19 North Carolina Dashboard (NCDHHS)

        North Carolina Department of Health and Human Services (NCDHHS)’s dashboard  provides an overview on the metrics and capacities that the state is following.

        COVID-19 metrics calculated include daily cases and tests, hospitalizations, and county/zip code-level case mapping. Other plots examine contact tracing, protective equipment (PPE), COVID-like illnesses, and outbreaks in congregate living settings. The data is based on COVID-19 case results submitted by North Carolina clinics and laboratories to NCDHHS.

      • UNC COVID-19 Dashboard

        The Coronavirus Dashboard from UNC Gillings School of Global Public Health provides relevant local COVID-19 research to all North Carolinians. Site also includes Coronavirus in NC by the Numbers, including an interactive visualization of coronavirus cases in NC.

      • COVID-19 Cases, Data and Surveillance (CDC)

        The Centers for Disease Control and Prevention hosts summary information and an Interactive Tracker related to COVID in the United States.

        Case, hospitalization, and death data is presented, as well as total numbers reported among healthcare personnel. Data is reported by US states to the CDC.

        Death statistics based on death certificates, which are more accurate but take longer to report, are tracked on the CDC’s National Center for Health Statistics page.

      • Novel Coronavirus Situation (WHO)

        Use this for global case data.

        The World Health Organization presents official daily COVID case and death counts comparatively across global regions and countries, showing daily, weekly, and cumulative counts. The counts are reported by countries to WHO. Uniquely, WHO includes a lens of viewing countries according to their self-reported transmission classification (for instance, clusters of cases or larger outbreaks of cases).

      • Coronavirus COVID-19 Global Cases (Johns Hopkins)

        Use this to see total cases, in comparison to other countries.

        Led by Johns Hopkins University Center for Systems Science and Engineering, this tracker shows total confirmed cases, broken down by country, state, and, for the US, the county. It also tracks the total deaths by country, and for the US, the total tests, hospitalizations, deaths per state. The data comes from US state and county health departments, non-US government health departments, and other data sources such as the World Health Organization and the CDC. The dashboard reports in real time using an automated update, and has thus been able to capture new cases in global countries earlier than other data sources

      • COVID-19 Projections (Institute for Health Metrics and Evaluation)

        Use for impact forecasting.

        The Institute for Health Metrics and Evaluation’s COVID-19 tracker shows how different policy decisions on social distancing mandates and mask use could affect the trajectory of the pandemic within select countries and states. It aggregates data from a variety of sources, including Johns Hopkins University, World Health Organization, and hospital networks.

      • COVID-19 Data Insights Tool (RTI)

        RTI’s COVID-19 Data Insights tool introduces a measure of estimated acquired immunity, providing basic insights into the level of immunity resulting from reported COVID-19 infections to date.

      • COVID-19 Data Hub (US Census Bureau)

        Use for business and demographic data in the US.

        The COVID-19 data hub provides demographic and economic information from existing surveys to reveal state and county risk factors. It also posts interactive results from weekly surveys about small business conditions and household experiences during COVID-19, as well as weekly updates about the number of business applications at national, regional, and state levels.

      • COVID-19/Coronavirus Facts and Figures (Statista)

        Use for charts related to COVID-19, but not all information is available using a free account.

        The Statista research team has compiled statistics, surveys, and forecast plots and dossiers using data from a variety of sources and their specified time periods. Examples of plots include number of confirmed cases by state, hospitalizations, public awareness, and economic impact. External links in the plots take users to the data source used. Updates to individual statistics plots can be retrieved through an optional notification alert on the plot.

      • The COVID Tracking Project (The Atlantic)

        Use to see total cases, in comparison to other US states.

        The COVID Tracking Project, launched by volunteers from The Atlantic, publishes data visualizations about cases, tests, hospitalizations and patient outcomes (recovered/death), in addition to racial data to show how COVID-19 impacts vulnerable communities. It reports only at the state level from public health authorities, in order to avoid inconsistently providing data from non-reporting counties. Rather than focusing on positive cases, the COVID Tracking Project collects complete testing data (positive and negative tests) because this provides context to the cases.

      • CARES Act (Federal Coronavirus Aid Package)
        The Coronavirus Aid, Relief, and Economic Security (CARES) Act established several new temporary programs administered through the SBA to address the COVID-19 outbreak.

        • SBA Payroll Protection Program
          A new round of funding for PPP loans was signed into law in late December 2020. 
          The Payment Protection Program forgivable loans to small businesses to pay their employees during the COVID-19 crisis. The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities.

          The loan forgiveness application is available here. 
          Loan forgiveness details available from the SBA here. Simpler PPP forgiveness (for loans of $50,000 or less) details are available here.
           
        • Economic Injury Disaster Loan
          The EIDL program is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to coronavirus (COVID-19). The SBA has extended the application deadline to December 31, 2021.
           
        • SBA Express Disaster Bridge Loan
          If a small business has an urgent need for cash while waiting for decision and disbursement on Economic Injury Disaster Loan, they may qualify for an SBA Express Disaster Bridge Loan of up to $25,000.
           
        • SBA Debt Relief
          The SBA will automatically pay the principal, interest, and fees of current 7(a), 504, and microloans for a period of six months.The SBA will also automatically pay the principal, interest, and fees of new 7(a), 504, and microloans issued prior to September 27, 2020

        Guidance:

        • Coronavirus (COVID-19): Small Business Guidance & Loan Resources (SBA)
        • See the Small Business Owner's guide to the CARES Act here. 
        • The SBTDC's SBA Loan overview is available here, or see their full COVID-19 resource guide here.
      • Main Street Lending Program (Federal Reserve)

        The Federal Reserve established the Main Street Lending Program (Program) to support lending to small and medium-sized businesses and nonprofit organizations that were in sound financial condition before the onset of the COVID-19 pandemic. Five-year loans are in the amount of $100,000 to $300 million.

      • North Carolina Business Reopening Resources (EDPNC) 

        The Economic Development Partnership of North Carolina has compiled some those resource to help manage operations during the “new normal,” emphasizing that businesses always need to follow protocols set by the governor and local and state health officials.

      • CARES Revolving Loan Fund
        This fund from United Durham Inc.'s Community Development Corporation capitalizes a revolving loan fund of $500,000 to address the economic development needs of small businesses and entrepreneurs adversely affected by the coronavirus pandemic. The Revolving Loan Fund is supported by a CARES Act Recovery Assistance grant awarded to UDI in July by the federal U.S. Economic Development Administration.

      • Orange County Emergency Small Business Funding Program - COVID-19
        Application deadline for Round #3: January 30, 2021

        The purpose of the Orange County Emergency Small Business Funding Program is to assist Orange County-based small businesses that are experiencing financial difficulties such as mandated shutdowns, employee layoffs, and operating losses as a result of ongoing efforts at the Federal, State and local authorities to contain and minimize the spread of the COVID-19 pandemic. Businesses who have already received COVID-19 related financial assistance from either the state, federal or local governments are not eligible to apply for this round of funding

      • COVID-19 Mecklenburg Small Business Emergency Stabilization Loan
        In recognition of the short and long-term impact that COVID-19 is having on the county’s entrepreneurial ecosystem, Mecklenburg County government has established a loan fund in partnership with the Carolina Small Business Development Fund. The fund provides affordable financing in amounts ranging from $5,000 to $35,000 for qualifying small businesses that have been adversely impacted by the pandemic.   Funds may be used to cover the day-to-day operating expenses of the business.

      • COVID-19 Federal Rural Resource Guide (USDA)
        USDA and its Federal partners have programs that can be used to provide immediate and long-term assistance to rural communities affected by the COVID-19 outbreak. These programs can support recovery efforts for rural residents, businesses and communities through technical, training and management assistance; financial assistance; and state and local assistance.

      • NC Covid-19 Rapid Recovery Loan Program (Golden LEAF Foundation)
        Applications are closed.
        In response to the unique economic challenges of COVID-19, a consortium of public, private, and nonprofit partners have come together and launched an innovative recovery-lending program to help support entrepreneurs like you and stabilize North Carolina’s small business sector.

      • Job Retention Grant (NC Department of Commerce)
        Applications are closed as of October 15, 2020. 
        If your business or non-profit organization experienced interruption due to the COVID-19 coronavirus pandemic, the new Job Retention Grant (JRG) Program may be able to offer assistance. Grants of up to $250,000 for businesses and nonprofits in North Carolina. 

      • NC Community Confidence

        Community Confidence is a decision support tool for Government and Business leaders to use when making important decisions that will impact their communities during the pandemic or other significant health challenges. This initiative is a collaboration between the Digital Health Institute for Transformation (DHIT), the Institute for Convergent Sciences and Innovate Carolina at the University of North Carolina, Chapel Hill. This project is being funded by the North Carolina Policy Collaboratory as part of the 2020 COVID-19 Recovery Act.

      • Greenlight Durham

        Greenlight Durham, a partnership with the City and County of Durham and Duke Health, provides free COVID-19 support including monitoring, guidance, and testing access to businesses in Durham.

      • Scientific Workplace Strategy: Expert planning to re-occupy safely and economically (Flad Architects)

        The recent and ongoing COVID-19 Pandemic is requiring new paradigms and a fundamental shift in how we think about research design and space use at all levels of interaction. With the goal of lessening density and creating safer environments, many perspectives will be needed to plan for safe and effective solutions.

      • Open Safely
        These recommendations for #OpenSafely were published in on May 20, 2020 by a group of bipartisan health policy experts and leaders from broad and diverse backgrounds including Andy Slavitt; Mark McClellan, MD, PhD; and others.

      • Guidance on Returning to Work (OSHA)

      • Reopening Decision Tree (CDC)
        The purpose of this tool is to assist employers in making (re)opening decisions during the COVID-19 pandemic, especially to protect vulnerable workers. It is important to check with state and local health officials and other partners to determine the most appropriate actions while adjusting to meet the unique needs and circumstances of the local community.

      • Reopening Your Business (The Chamber for a Greater Chapel Hill-Carrboro)
        A guide to provide organizations with the best known guidance to ensure consumer confidence and promote community health in the age of COVID-19.

      • Re-entry Guidance for Health Care Facilities and Medical Device Representatives (AdvaMed)

        In response to the COVID-19 pandemic, hospitals and surgical facilities nationwide paused elective surgical procedures and other nonemergent and nonessential services, limiting physical access to facilities for nonessential health care personnel, patient visitors, and medical device representatives.

      • Navigating Your Business Through COVID-19 (SBTDC)

        COVID-19 has disrupted the lives of millions and is having significant impacts on businesses. North Carolina’s small business service providers are here to help you navigate this unprecedented event.

         

      • Small Business Center Network COVID-19 Resources

        The Small Business Center Network of North Carolina is here to help you navigate challenges associated with COVID-19. Funded by your tax dollars, our services are free.

      • Duke Margolis Center for Health Policy COVID-19 Response
        Duke-Margolis faculty and researchers from Duke University and Duke Health System, and leaders from across the health care and health policy landscape are working together to advance collective recommendations to address the COVID-19 pandemic. The Center will be releasing new working papers, holding informational webinars, and centralizing useful resources for the policy community in the coming days and weeks.

      • Updates from the FDA (FDA)

      • Interim Guidance for Businesses and Employers (CDC)
        This interim guidance is based on what is currently known about the coronavirus disease 2019 (COVID-19). The Centers for Disease Control and Prevention (CDC) will update this interim guidance as needed and as additional information becomes available.

        Also see the CDC's Business Pandemic Influenza Planning Checklist and Pandemic Preparedness Planning for US Businesses with Overseas Operations.

      • Information for Laboratories (CDC)
        This page includes interim guidance and resources for laboratory professionals working with specimens from persons under investigation (PUI) for coronavirus disease 2019 (COVID-19).

      • Worker Training Program (NIEHS)
        The NIEHS Worker Training Program (WTP) has been tracking information about the coronavirus disease 2019 (COVID-19) as it pertains to protecting workers involved in emergency response and cleanup activities performed in the United States. This page contains health and safety resources for workers who may be at risk of exposure to COVID-19.

      • Ultimate Guide to Supply Chain Resiliency Success (Resilinc)
        This document provides supply chain risk management and resiliency strategies and practices.

      • Best Practices for Establishing a Cross-Functional Team (NC Chamber)
        This best practice document offers guidance on establishing a cross-functional team tasked with preparation, communication and incident response.

      • COVID-19 Control and Prevention (OSHA)
        OSHA has developed this interim guidance to help prevent worker exposure to COVID-19.

        Also see OSHA's 2017 Guidance on Preparing Workplaces for an Influenza Pandemic.

      • Business and Employer Preparation Guidance (North Carolina DHHS)
        Also read about NCDHHS and NC Emergency Management's COVID-19 response and preparation here

      • Strategic Preparedness and Response for the new coronavirus (WHO)
        This strategic preparedness and response plan outlines the public health measures that the international community stands ready to provide to support all countries to prepare for and respond to COVID-19.

      • Travel Guidelines (CDC)
        This page includes information about Coronavirus Disease 2019 (COVID-19) for travelers and travel related industries.

        Also see RDU Airport's travel updates here.

      • Healthcare Planning Checklist (DHHS)
        Planning for a potential emerging infectious disease pandemic, like COVID-19, is critical to protecting the health and welfare of our nation. This checklist identifies specific activities your jurisdiction can do now to prepare for, respond to, and be resilient in the face of COVID-19.

      • Families First Coronavirus Response Act: Employer Paid Leave Requirements (US Department of Labor)
        The Families First Coronavirus Response Act (FFCRA or Act) requires certain employers to provide their employees with paid sick leave or expanded family and medical leave for specified reasons related to COVID-19. This page provides guidance about this new law.

        Also see this Q&A with Hutchison PLLC regarding these new requirements.

      North Carolina Covid-19 News

      NCBiotech, 12/28/2020

      BioCryst Stops COVID-19 Work to Target Other Viral R&D

      BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. But SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them. The Durham company has reported early stage clinical trial results showing that treatment with the experimental antiviral offered COVID-19 patients no benefit compared to a placebo. 

        Read More
      Triangle Business Journal, 12/23/2020

      What are long-term effects of Covid-19 vaccine? DCRI will find out.

      As millions of Covid-19 vaccine doses are distributed across the country and globe, a Triangle contract research organization (CRO) has been commissioned to lead a study on the long-term effects of one of the vaccines. Duke Clinical Research Institute (DCRI) has been hired by Pfizer (NYSE: PFE) to gain long-term insights about the vaccine developed in partnership with BioNTech, including "real-world safety data."

        Read More
      WRAL TechWire, 12/17/2020

      Hillsborough native, UNC graduate helped develop COVID-19 vaccine

      (CNN) -- Dr. Anthony Fauci and Gov. Roy Cooper are both praising Dr. Kizzmekia Corbett, a University of North Carolina Chapel Hill graduate and a Hillsborough native, for her work to help develop a coronavirus vaccine. Fauci is urging Black Americans hesitant to take the COVID-19 vaccine to trust the process -- in part because one of the scientists at the forefront of the vaccine's development is a Black woman.

        Read More
      NCBiotech, 12/17/2020

      Heat Biologics Looks to Phase 1 Tests of COVID-19 Vaccine

      Heat Biologics, a clinical-stage immunotherapies developer, is moving closer to human testing of a vaccine for COVID-19. The Morrisville-based biotech reported preclinical data showing that its vaccine candidate, ZVX-60, prompted the expression of two proteins key to an immune response. The Heat vaccine also led to the expression of the “spike protein” characteristic of the novel coronavirus.

        Read More
      Triad Business Journal, 12/10/2020

      FDA approves LabCorp's at-home Covid-19 testing kit

      LabCorp, a leading global life sciences company, has announced that the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the first Covid-19 home test. The Pixel by LabCorp Covid-19 Test Home Collection Kit will be the first to be available over-the-counter without requiring a prescription. 

        Read More
      Triangle Business Journal, 11/30/2020

      Raleigh drugmaker with Covid treatment in pipeline expands manufacturing capacity

      A Triangle drugmaker says it's expanding manufacturing capacity is the U.S. ahead of an expected emergency use authorization for its treatment for Covid-19.

      Raleigh's RedHill Biopharma (Nasdaq: RDHL) says it has inked partnerships with two U.S. based manufacturers for "large scale" production of its drug, opaganib.

        Read More
      Triad Business Journal, 11/29/2020

      Covid-19 affects people differently. NC firm looks to figure out why.

      A well known phenomenon of the Covid-19 era is that the deadly virus presents a wide disparity of symptoms between patients – now a Triangle firm has the federal funding to try to find out why.

      Last week, Morrisville-based Metabolon was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to be a lead in its "Immunophenotyping Assessment in a Covid-19 Cohort," or IMPACC, study.

        Read More
      Triangle Business Journal, 11/25/2020

      NC State scores $400K to boost face mask performance, production

      Researchers at N.C. State will be working to improve the quality and performance of face masks thanks to a new grant – another marker for how the university's textile expertise is being leaned on during the Covid-19 crisis. Last week, the university's Nonwovens Institute (NWI) announced a $400,000 grant from The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), earmarked to "investigate improving the properties of materials" being used for masks and respirators.

        Read More
      WRAL TechWire, 11/25/2020

      Next-generation respirator mask to be manufactured in Jacksonville

      A new type of resiprator mask from Pittsburgh-based MSA Safety Inc. will be produced at the firm’s factory in Jacksonville, the company announced Wednesday.

      Called the Advantage 290 LS Air-Purifying Respirator, it is the first mask “of its kind” to win approval from the National Institute for Occupational Safety and Health. The mask is reusable. And the company notes that NIOSH approved masks “including elastomeric half-mask respirators (EHMRs), are appropriate for use against SARS-CoV-2 in healthcare settings.”

        Read More
      Triangle Business Journal, 11/19/2020

      Enormous RTP campus will employ up to 650 to produce Covid vaccine doses

      An enormous campus planned for Research Triangle Park will have the capacity to produce billions of injection devices for the mass delivery of vaccines.

      Connecticut-based ApiJect Systems announced Thursday it will build a 185-acre campus, with a potential cost of $785 million, in RTP that will include a gigafactory and up to 650 jobs. ApiJect, which makes an experimental disposable injection device, said the 1-million-square-foot campus will be capable of producing 3 billion single-dose prefilled injectors annually.

        Read More
      Triangle Business Journal, 11/18/2020

      Durham firm ready to play crucial role in Covid vaccine distribution

      As both Pfizer and Moderna inch closer to approved Covid-19 vaccines, companies are lining up to support the effort – including in the Triangle, where local innovation could help solve a big challenge for distribution – how to keep the vaccines cold.

      Phononic, a Durham refrigeration technology firm with more than $160 million in venture capital dollars in its coffers, has already been part of the distribution conversation, according to Keith Lewis, director of business development and strategic partnerships.

        Read More
      NCBiotech, 11/17/2020

      Ventilator Maker IPM Chirana Picks RTP for US Headquarters

      IPM Chirana, a global company that makes ventilators to treat critical-care patients, has selected North Carolina's Research Triangle Park as the home of its U.S. headquarters. The new site opens as COVID-19 cases mount across the country and around the world, driving demand for medical equipment such as IPM Chirana's ventilators.

        Read More
      NCBiotech, 11/16/2020

      Verona Pharma, with a Raleigh HQ, Weighs its COPD Candidate as COVID-19 Therapy

      A British clinical-stage biotech firm with U.S. headquarters in Raleigh is exploring the option of repurposing its leading drug candidate to treat COVID-19 patients. Flush with $200 million after a July raise, the London-based Verona Pharma is already making big strides with its “first-in-class” drug, ensifentrine, targeting chronic obstructive pulmonary disease (COPD).

        Read More
      WRAL TechWire, 11/13/2020

      GSK, Medicago – which has big plant in RTP – taking potential COVID-19 vaccine to next stage

      Two life science firms with a big presence in the Triangle are continuing to develop a potential vaccine for COVID-19. GlaxoSmithKline and Medicago announced their partnership in July and on Thursday said the vaccine is proceding to stage two clinical trials. Medicago is based in Canada but has a big operation in RTP.

      The companies are developing a COVID-19 vaccine that combines the latter’s Coronavirus Virus-Like Particles with GSK’s adjuvant.

        Read More
      WRAL TechWire, 11/10/2020

      Could wearables detect COVID-19, other illnesses? RTI, Pentagon, Garmin to find out

      That wearable device on your wrist to track your steps and heartbeat could also be a means of detecting an illness such as COVID-19. Or so researchers at RTI International and device maker Garmin are going to find out. In a project unveiled Tuesday, RTI said it’s working with Garmin with the support of the Pentagon’s Defense Advanced Research Projects Agency to determine if collecting more data from wearable devices at more frequent intervals improves disease detection.

        Read More
      NCBiotech, 11/3/2020

      Carolina’s Coronavirus Lab

      Long before the novel coronavirus began its spread across the world, Ralph Baric and Timothy Sheahan were suiting up in full-body protective equipment. Baric, in particular, has been studying coronaviruses for nearly four decades.

        Read More
      Triangle Business Journal, 10/23/2020

      To fight Covid, Duke and UNC researchers make living 'mini-lung'

      Thanks to work by scientists at local universities, researchers will now be able to study Covid-19 infections in lab-grown lungs. A new paper outlining research conducted by researchers at Duke University and UNC-Chapel Hill shows how the team has created a "lab-grown living lung model" that mimics the tiny air sacs – alveoli – in the human lung, meaning researchers can now study how the disease affects lungs in a laboratory setting.

        Read More
      NCBiotech, 10/9/2020

      Grifols Begins Phase 3 Testing for COVID-19 Treatment

      Grifols, a global biotherapeutics company, has begun Phase 3 clinical trials in patients with COVID-19 with its therapeutic manufactured in Clayton.

        Read More
      News & Observer, 10/7/2020

      UNC research center is one of the leaders in the race to find a COVID-19 vaccine

      The University of North Carolina at Chapel Hill is one of 89 testing sites for Moderna’s phase 3 clinical trial for a COVID-19 vaccine. Because of its quick response and extensive research, UNC-CH has become among the most cited universities in the U.S. for coronavirus expertise.

        Read More
      NCBiotech, 10/6/2020

       

      LabCorp’s Improved COVID-19 Test OK’d for Emergency Use

      Burlington-based LabCorp, a leader in COVID-19 testing, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration to deploy an improved laboratory test for detecting the coronavirus infection.

        Read More
      WRAL TechWire, 10/5/2020

      Winston-Salem surgeon addresses mask shortage by launching a company

      By the end of December 2019, Gajendra Singh, M.D., a surgeon in Winston-Salem experienced a  shortage of masks for use in his office. The shortage lasted for several months and his practice suffered as the COVID pandemic spread, impacting the low-cost services his office provides.

      He managed to buy masks online for the relatively high price of $45 a box, but that didn’t seem like a viable option. So, Singh, following the dictum that has launched a thousand startups — find a need and fill it — created GS Medical.

        Read More
      NCBiotech, 9/30/2020

      Carolina Liquid Chemistries Adds Another COVID-19 Test To Lineup

      Greensboro diagnostics and drug screening company Carolina Liquid Chemistries has added another COVID-19 test kit to its product line. CLC says it’s now selling the FaStep COVID-19 IgG/IgM Rapid Test Device, made by Chinese manufacturer Assure Tech, (Hangzhou) Co., Ltd. 

        Read More
      Duke News, 9/28/2020

      Window for Slowing COVID’s Spread was Smaller than Projected

      A new Duke University-led analysis shows that during the early months of the COVID pandemic, the average number of new infections caused by an infected individual (i.e. the basic reproduction number, R0) was 4.5, or more than twice as many as the initial 2.2 rate estimated by the World Health Organization at the time.

        Read More
      Triangle Business Journal, 9/15/2020

      NC State tapped to solve logistical challenges in Covid testing

      Throughout the pandemic, the shortage of testing kits has been a persistent issue lamented by public health officials and providers across the nation. Now, researchers at N.C. State are tasked with developing a model to address logistic efficiency. This week, researchers at the university announced they've received a one year, $600,000 grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) earmarked to address the logistics of Covid-19 testing kit allocation.

        Read More (article behind paywall)
      WRAL TechWire, 9/11/2020

      RTP biotech backed by Jim Goodnight says nitric oxide can fight COVID-19

      KNOW Bio, a biotech backed by SAS cofounder and CEO Jim Goodnight, says it has demonstrated the “first definitive evidence” that nitric oxide can fight the coronavirus that causes COVID-19. The findings come as the search continues for a vaccine and other means to fight the deadly pandemic.

       

        Read More
      WRAL TechWire, 9/9/2020

      Duke researchers seek FDA approval for solution to split ventilators between patients

      Researchers at Duke University have engineered a workaround to make ventilators safer and more efficient when splitting them between patients. With a set of biocompatible 3D-printed parts to control the amount of air being pushed to each patient and hundreds of thousands of hours of complex computer simulations to decide which of those parts to use, the innovative system has been submitted for emergency FDA approval for use.

        Read More
      NCBiotech, 9/8/2020

      RedHill’s Potential COVID-19 Drug Shows ‘Potent’ Antiviral Effect

      RedHill Biopharma, an Israeli company with U.S. headquarters in Raleigh, says one of its drug candidates, opaganib, completely inhibited the replication of the coronavirus that causes COVID-19 in a laboratory study.

        Read More
      NCBiotech, 9/8/2020

      LabCorp Launches First Combined Test for COVID-19, Flu and RSV

      Burlington-based LabCorp has developed the first testing method to simultaneously detect for COVID-19, influenza A / B, and respiratory syncytial virus (RSV) just in time for the upcoming flu season. The single-panel test is initially available to patients through doctors, hospitals and other authorized healthcare providers nationwide. But LabCorp is also seeking approval from U.S. Food and Drug Administration for an at-home version. 

        Read More
      Triangle Business Journal, 9/1/2020

      A Durham firm collected data from thousands of Covid patients. Here's what it found.

      A Triangle data firm says its analysis of data from thousands of Covid-19 patients is providing detailed insight into the major risk-factors associated with the disease. Durham-based Target RWE has published the initial analysis of its growing data set in the journal Clinical Infectious Diseases. The company, which focuses on creating real-world evidence for pharmaceutical and biotech companies, says its current data set has exceeded more than 70,000 patients. 

        Read More (Article behind paywall)
      NCBiotech, 8/31/2020

      NIAID Awards BioCryst $44M for COVID-19 Treatment Work

      Durham’s BioCryst Pharmaceuticals has landed a new federal contract totaling $44 million and added some $3 million to an existing contract to support the development of galidesivir as a possible COVID-19 treatment. The funding is from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

        Read More
      NCBiotech, 8/24/2020

      BioAgilytix Pairs with BRIO Systems for Employers Seeking COVID-19 Testing Programs

      Durham based BioAgilytix Labs has partnered with Boston’s Brio Systems to launch a platform to provide U.S. employers comprehensive COVID-19 testing programs. BioAgilytix, a bioanalytical laboratory with a diagnostic testing division, said the launch of the product, dubbed COVIDence, offers a one-stop solution to manage employee testing and mitigate exposure within workforces.

        Read More
      Triangle Business Journal, 8/16/2020

      Novavax, partnering with Morrisville firm, lands Covid-19 vaccine deal with U.K.

      Novavax Inc. has locked in a deal to provide 60 million doses of its Covid-19 vaccine to the United Kingdom, the latest of multiple agreements the Maryland biotech has inked in the past week. Deal terms were not disclosed. Novavax (Nasdaq: NVAX) said it will expand its partnership with Tokyo-based Fujifilm Diosynth Biotechnologies to make the antigen for its candidate, NVX-CoV2373, including 180 million doses at the latter's U.K. site each year. 

        Read More (Behind paywall)
      Triangle Business Journal, 8/14/2020

      Raleigh pharma gets FDA approval to explore Covid-19 treatment

      Coming fresh off a $200 million raise, a drugmaker with a growing operation in the Triangle has received the go-ahead from the U.S. Food and Drug Administration to test one of its drugs as a treatment for Covid-19. On Friday, Verona Pharma reported the FDA gave the company notice is can proceed with a investigational new drug (IND) trial of ensifentrine in patients with Covid-19.

        Read More
      NCBiotech, 8/13/2020

      RTI Team Accelerating Research on COVID-19, Treatments

      Federal health officials have tapped RTI International to join a collaboration tracking COVID-19’s ability to cause severe illness and the effectiveness of proposed treatments. The initiative, called  Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies, or CONNECTS, is being led by the National Heart, Lung and Blood Institute, part of the National Institutes of Health.

        Read More
      Triad Business Journal, 8/7/2020

      Kepley Biosystems develops process to clean air of viruses like Covid-19

      A person sneezes, coughs or produces spittle while talking. The droplets then land on the sleeve of the listener, who carries with him or her for the rest of the day the potential to infect friends or family members with a deadly virus or disease. Thus the need for social distancing, mask wearing and other means of transmission prevention during the current pandemic.

      But imagine if, rather than carry around for several hours a ticking time bomb, the listener’s clothes –– infused with a functionalized molecule –– were able to absorb and destroy the microbial material or virus on contact. 

        Read More (Note: Behind paywall)
      WRAL TechWire, 8/7/2020

      Here’s how Triangle life science industry is working overtime to defeat COVID-19

      By Ryan Combs, Executive Director of the Research Triangle Regional Partnership
      As the world continues to recover and look for solutions to address COVID-19, I wanted to take a moment to highlight a few of the incredible contributions the state of North Carolina has made toward one of the world’s biggest challenges to date.

        Read More
      WRAL TechWire, 7/31/2020

      Grifols Produces First Batches of Potential COVID-19 Therapeutic for Testing

      Grifols, a global biotherapeutics company with major operations in North Carolina, has delivered the first batches of a therapeutic product manufactured in Clayton that could help prevent and treat COVID-19 infection. Doses of the company’s hyperimmune globulin are ready for clinical trials that will test the product’s safety and effectiveness in combating SARS-CoV-2, the virus that causes COVID-19.

        Read More
      NCBiotech, 7/30/2020

      Carolina Liquid Chemistries Offers COVID-19 Test Kits

      Greensboro diagnostics and drug screening company Carolina Liquid Chemistries (CLC) is now selling COVID-19 test kits. CLC said it offers two real-time RT-PCR (reverse transcriptase polymerase chain reaction) tests that detect nucleic acid from SARS-CoV-2 in people who have contracted the coronavirus. SARS-CoV-2 is the virus that causes COVID-19. The diagnostics can identify the macromolecules in nasal and throat swabs and sputum.

        Read More
      WRAL TechWire, 7/30/2020

      Durham’s Velocity Clinical lands 5 contracts for Phase 3 COVID-19 vaccine trials

      Velocity Clinical Research is playing a big part in the global race to find a COVID-19 vaccine. The Durham-based clinical trial company has received multi-site awards for five of the phase III COVID-19 vaccine studies announced to date. It will conduct 14 studies in total across eight sites in Ohio, California, Texas, Rhode Island, Utah, Idaho and Oregon.

        Read More
      Triangle Business Journal, 7/29/2020

      Heat Biologics: Covid-19 vaccine candidate shows promise in animal testing

      A Triangle drugmaker pursuing a Covid-19 vaccine is reporting that pre-clinical testing of its vaccine candidate is showing early success. On Wednesday, Morrisville-based Heat Biologics (Nasdaq: HTBX) announced that "successful pre-clinical testing" of the company's vaccine for Covid-19 demonstrated " in-vivo confirmation of vaccine immunogenicity in animal models" including the expansion of a T-cell response against the virus.

        Read More
      WRAL TechWire, 7/29/2020

      Pence praises speed, safety of coronavirus vaccine work

      For the second time in three days, the Trump administration focused its attention on coronavirus vaccine development work being done in North Carolina. Following in the footsteps of President Donald Trump, who toured a Morrisville plant on Monday where a vaccine candidate is being produced, Vice President Mike Pence met Wednesday with researchers conducting clinical trials on a second potential vaccine. Wake Research is enrolling thousands of volunteers to test a vaccine developed by Moderna, which entered Phase III trials this week, the final stage before possible approval by the U.S. Food and Drug Administration.

        Read More
      NCBiotech, 7/28/2020

      Patent Issued for 9 Meters Biopharma’s Potential COVID-19 Treatment

      Thinking outside the gut, a Raleigh pharmaceutical upstart is landing support for exploring its tissue-tweaking technology as a possible extension from gastrointestinal disorders to lung problems. That’s why 9 Meters Biopharma has secured patent protection for its potential approach to treating lung disease. 

        Read More
      NCBiotech, 7/28/2020

      IQVIA Initiative Gives COVID-19 Researchers Free Access to Global Data

      Research Triangle Park-based contract research giant IQVIA has launched a program that waives licensing and access fees for approved academic researchers as part of its efforts to accelerate research on how COVID-19 is impacting the healthcare industry and related treatment.

        Read More
      NCBiotech, 7/23/2020

      NC's COVID-19 Biomanufacturing Prowess Draws Presidential Visit

      North Carolina’s global leadership in biomanufacturing has drawn another spotlight with a White House announcement that President Donald Trump will be visiting the Triangle on Monday, July 27, to a company involved in producing COVID-19 vaccine.

        Read More
      UNC Chapel Hill University Communications, 7/22/2020

      North Carolina Policy Collaboratory distributes $29 million for COVID-19 research

      The North Carolina Policy Collaboratory based at UNC-Chapel Hill will distribute $29 million toward 85 research projects focused on treatment, community testing and prevention of COVID-19. These research projects are intended to provide new data and information to North Carolina lawmakers and policymakers to help guide the state’s pandemic response. The collaboratory will be required to provide an update to the North Carolina General Assembly in September about the status of its research projects, which will be occurring across 14 UNC System campuses.

        Read More
      Duke Today, 7/22/2020

      Duke to start trial of promising COVID antibody treatment

      The Duke Human Vaccine Institute (DHVI) has been given approval to launch a Phase 1 clinical trial of one of its most promising antibody treatments for COVID-19. This would be a temporary treatment until a vaccine is developed.

        Read More
      NCBiotech, 7/20/2020

      Chapel Hill’s Path BioAnalytics Joins COVID-19 Battle

      Chapel Hill-based Path BioAnalytics (PBA) has joined forces with Australian researchers to study a new drug to fight SARS-related Coronoavirus-2, the virus that causes COVID-19.

        Read More
      WRAL TechWire, 7/15/2020

      UNC-Chapel Hill scores $433,000 grant to speed up COVID-19 research

      The Chan Zuckerberg Initiative recently awarded a $433,000 grant to the University of North Carolina at Chapel Hill (UNC) for laboratory equipment that will accelerate research to address the COVID-19 pandemic, potentially saving lives. The equipment will go to the lab of Ralph Baric, PhD, William R. Kenan Jr. Distinguished Professor of epidemiology at the UNC Gillings School of Global Public Health.

        Read More
      WRAL TechWire, 7/14/2020

      Iqvia teams with AstraZeneca for COVID-19 vaccine project

       Life sciences giant Iqvia is teaming with international pharmacerutical firm AstraZeneca in an attempt to accelerate development of a COVID-19 vaccine.The AstraZeneca-Iqvia partnership will be included in the “Operation Warp Speed” COVID-19 vaccine effort launched by the Trump Administration.

      WRAL TechWire, 7/9/2020

      Biotherapeutic company Grifols developing COVID-19 treatment

      An inside look at the making of a new COVID-19 treatment is playing out in Johnston County. The biotherapeutic company Grifols is hoping to send the first doses of their new medication to clinical trials sometime in July. The treatment uses donated plasma from people who have recovered from COVID-19.  The antibodies are then extracted from the plasma that’s purified before it’s then given to patients by transfusion.

        Read More
      NCBiotech, 7/7/2020

      Medicago and GSK Collaborating on Plant-Based COVID-19 Vaccine

      An ancient relative of tobacco is at the heart of a new COVID-19 vaccine under development by Medicago and GSK. The two biopharmaceutical companies are working together to create a COVID-19 therapy that combines Medicago’s plant-based recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.

        Read More
      NCBiotech, 7/7/2020

      LabCorp Launches Another COVID-19 Solution

      Burlington-based LabCorp is offering a new home-based testing service to screen patients for COVID-19 infections before they proceed with surgeries and other important medical treatments. The At Home COVID-19 Test Collection Service received Emergency Use Authorization from the U.S. Food and Drug Administration on July 1.

        Read More
      NCBiotech, 6/26/2020

      Kepley BioSystems Developing Air Sterilization Masks Targeting COVID-19

      Greensboro-based Kepley BioSystems, Inc. has joined the growing number of North Carolina life sciences companies refocusing their wits resources to combat the spread of COVID-19.

        Read More
      NCBiotech, 6/26/2020

      LabCorp’s New Test May Aid Vaccine, Therapy Development for COVID-19

      Burlington-based LabCorp has launched a new test that it says may be helpful in battling the COVID-19 pandemic. The test is a neutralizing antibody assay that assesses the capacity of antibodies in patient plasma to inhibit SARS-CoV-2, the novel coronavirus that causes COVID-19 infections.

        Read More
      NCBiotech, 6/24/2020

      Experimental RedHill COVID-19 Drug Logs Positive Results

      RedHill Biopharma is reporting positive early results from one of its potential treatments for COVID-19. The Israeli company, which has its U.S. headquarters and commercial operations in Raleigh, says five Israeli patients hospitalized with severe COVID-19 infections showed substantial benefit from its novel drug, opaganib​ (Yeliva, ABC294640).

        Read More
      WRAL TechWire, 6/23/2020

      Duke launches COVID-19 research project in Kannapolis, Cabarrus County

      Duke’s MURDOCK Study has launched a COVID-19 research project to follow the health of hundreds of North Carolina volunteers for several months. The study will also test a sub-group for COVID-19 infection and potential immunity to the novel coronavirus that causes the disease.

        Read More
      WRAL TechWire, 6/17/2020

      Duke, partners expand project tracking COVID-19 via smartwatches, phones

      Researchers at Duke University are expanding a recent study intended to help identify the symptoms of COVID-19, the disease caused by the novel coronavirus. This expanded effort will help the team establish a more comprehensive method of early-symptom detection and provide more information about how the virus can spread through a community.

        Read More
      NCBiotech, 6/17/2020

      Bio Products Laboratory USA Launches Plasma Therapies, Enters COVID-19 Fray

      BPL has joined the recently formed CoVIg-19 Plasma Alliance, a partnership of world-leading plasma companies that are combining their research and resources in the hunt for a COVID-19 plasma treatment. The Alliance hopes to develop an immunoglobulin (Ig) therapy, CoVIg-19, that could help protect vulnerable groups until a vaccine can be successfully developed, clinically tested and supplied.

        Read More
      NCBiotech, 6/15/2020

      Advanced Animal Diagnostics Pivots to Humans for COVID-19 Test, With NCBiotech Boost

      Advanced Animal Diagnostics, as the name suggests, makes tests for animals, not humans. However, in the age of coronavirus, this small ag tech company from Morrisville finds itself “repurposing” its QScout blood test platform -- designed to detect disease in cattle -- to now be used for screening COVID-19 in humans.

        Read More
      Triangle Business Journal, 6/12/2020

      Going Virtual: Triangle CROs have long seen the value in virtual trials. The pandemic made that a reality.

      Virtually overnight, the most basic business model of one of the Triangle’s largest industries collapsed. In the course of just weeks, the contract research organizations (CROs) that create thousands of Triangle jobs, and billions in revenue, by running clinical trials across the globe saw nearly all of their sites shutter.

        Read More (behind payroll)
      Triad Business Journal, 6/12/2020

      NC A&T, WSSU each receive $1 million to fight Covid-19

      Winston-Salem State University and North Carolina A&T University will both receive $1 million to put toward fighting Covid-19. The money, to be awarded July 1, is part of a total $6 million the UNC board of governors has awarded to each of the state’s university system historically minority-serving schools.  N.C. A&T said it plans to use the funding for multiple projects, from studies in both food and animal testing, affordable fever detection in K-12 schools, ways to cut down death rates among the elderly in assisted living facilities and the development of a nanoparticle that can kill the virus. 

        Read More
      WRAL TechWire, 6/12/2020

      UNC researchers create new type of COVID-19 antibody test

      As the COVID-19 pandemic continues with many thousands of new infections reported each day, there is a need for widely applicable surveillance testing to gain a better understanding of infection rates, especially the number of infections in people with mild or no symptoms, who can still be carriers. UNC School of Medicine scientists and colleagues developed a new kind of antibody test – a simplified experimental assay that could be ramped up to test thousands of blood samples at labs that do not have the resources of commercial labs and large academic medical centers.

        Read More
      NCBiotech, 6/11/2020

      Grifols begins manufacturing potential COVID-19 treatment at Clayton facility

      Grifols, a global biotherapeutics company with major operations in North Carolina, has begun producing the first specific COVID-19 drug at its manufacturing campus in Clayton. The company is producing hyperimmune immunoglobulin with specific antibodies, using the plasma of people who have overcome COVID-19, the disease caused by the novel coronavirus known as SARS-CoV-2.

        Read More
      NCBiotech, 6/10/2020

      Collaborations Pharmaceuticals, Built Around Collaborations, Now Targets COVID-19

      If you want to know what Collaborations Pharmaceuticals is all about, start with its name. The Raleigh-based startup is in the business of collaboration. It partners with the academic community, foundations and other companies to develop drugs that treat rare and neglected diseases. The goal is to advance promising new therapies from early stage development to clinical trials. The company has been  working on possible solutions for COVID-19 since early this year.

        Read More
      Wells Fargo Stories, 6/10/2020

      Accelerated award funding helps cleantech startups maintain momentum during COVID-19

      The Wells Fargo Innovation Incubator is awarding $900,000 to help clean technology and sustainable agriculture startups retain staff and stay on track to bring environmental solutions to market. For many recipients, the award will provide needed capital for their day-to-day operations and ongoing research projects. However, some awardees like Advanced Animal Diagnostics are using the funding to support a pivot to efforts directly tied to containing the spread of COVID-19.

        Read More
      NCBiotech, 6/10/2020

      NC startup secures FDA authorization for ‘low cost’ ventilator, brings NASCAR teams onboard

      Half a year into a global pandemic, a small North Carolina life sciences startup has gotten fast-track approval to start producing “low-cost, high-value” ventilators. Meet BioMedInnovations (BMI), headquartered outside Charlotte with a research lab in Research Triangle Park. This week, it received emergency use authorization from the U.S. Food and Drug Administration for its device called the SuppleVent, a back-pressure regulator-based ventilator.

        Read More
      NCBiotech, 6/9/2020

      BioMedInnovations Lands FDA OK for New SuppleVent COVID-19 Ventilator

      Half a year into a global pandemic, a small North Carolina life sciences startup has gotten fast-track approval to start producing “low-cost, high-value” ventilators. Meet BioMedInnovations (BMI), headquartered outside Charlotte with a research lab in Research Triangle Park. This week, it received emergency use authorization from the U.S. Food and Drug Administration for its device called the SuppleVent, a back-pressure regulator-based ventilator.

        Read More
      NCBiotech, 6/3/2020

      Atom Bioworks Gets NSF Grant to Work on COVID-19 Diagnostic

      Cary-based startup Atom Bioworks plans to use artificial intelligence and nanotechnology to design a rapid diagnostic for COVID-19. That initiative just got a big boost.  The National Science Foundation has awarded the company a $248,000 grant under its Rapid Response Research (RAPID) program. 

        Read More
      NCBiotech, 6/2/2020

      LabCorp Helps People Connect with COVID-19 Research Trials

      If you’re interested in participating in a clinical trial to solve some of the riddles of COVID-19, LabCorp can help you make that connection. The Burlington-based corporation’s Covance drug development business has created COVID-19 Clinical Trial Connect in the U.S., a website designed to help people find information about how they can take part in coronavirus research.

        Read More
      WRAL TechWire, 6/2/2020

      UNC study: Face masks may help since coronavirus often infects nasal cavities first

      In a major scientific study published in the journal Cell, scientists at the UNC School of Medicine and the UNC Gillings School of Global Public Health have characterized the specific ways in which SARS-CoV-2 – the coronavirus that causes COVID-19 – infects the nasal cavity to a great degree – replicating specific cell types – and infects and replicates progressively less well in cells lower down the respiratory tract, including the lungs.

        Read More
      Innovate Carolina, 6/1/2020

      Biomedical Engineering COVID-19 Response: Primed for pandemic innovation

      From developing face masks to vaccines, ventilators and diagnostics, a joint department at UNC-Chapel Hill and NC State fights COVID-19 by blending the best of medicine, engineering, teaching and more.

        Read More
      Duke Today, 5/27/2020

      Duke Launches National Network to Bring COVID-19 Support Directly to People

      The PRN is a network of organizations aligned to serve the needs of individuals and communities during the pandemic, especially those that are hardest-hit by COVID-19. PRN partners serve essential service workers and individuals who work in long term care; advocate for Hispanic communities and communities of older adults; provide medical care to vulnerable communities; and provide software products focused on employee information security and social service referrals.

      Read More

      NCBiotech, 5/21/2020

      Durham Medical AI Leader TeraRecon Makes Quick Shift to COVID-19 Imaging

      The last few years have been good to TeraRecon, a Durham company that builds comprehensive medical imaging software using artificial intelligence. In 2017, it released a large algorithm marketplace, and a year later it launched a “results explorer,” which displays the AI-processed images in an interactive and efficient dashboard that gives physicians optimum control.

        Read More
      NCBiotech, 5/21/2020

      Durham-based IQVIA to Manage Clinical Trial of Hydroxychloroquine Vs. COVID-19

      Durham-based IQVIA (NYSE: IQV) has been selected to manage COVID SHIELD, an Australian clinical study of hydroxychloroquine, the drug President Trump said he has been taking to prevent a COVID-19 infection.

        Read More
      Triangle Business Journal, 5/19/2020

      Duke's one-hour coronavirus antibody test could be a 'game-changer'

      As the world hunts for effective means for testing and screening populations for Covid-19, Duke University researchers have developed a test to detect antibodies for the virus – in less than an hour. In partnership with private industry, researchers at the Duke-NUS Medical School in Singapore have developed a new blood test that will detect the presence of neutralizing antibodies for Covid-19.

      Article behind paywall.

        Read More
      NCBiotech, 5/14/2020

      Orion Plans AI Strategy to Design Vaccines Against COVID-19

      Orion Integrated Biosciences, a Kansas-based biodefense company with a growing presence in North Carolina, plans to use artificial intelligence to design vaccines to fight COVID-19. The company says its vaccine design strategy will use powerful AI algorithms it developed from very large datasets of genomic information.

        Read More
      NCBiotech, 5/14/2020

      Grifols Expands Plasma Collection Centers in Search for COVID-19 Treatment

      If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find a potential treatment for the disease. Grifols, one of the leading producers of plasma-based medicines, is expanding its plasma collection program in North Carolina and beyond. The goal is to develop an immunoglobulin that can treat COVID-19.

        Read More
      Philanthropy, 5/13/2020

      A Star Medical Researcher Looks at the Coronavirus

      Dr. Tony Atala—an international leader in the field of regenerative medicine, which creates tissues that can replace failing body parts—discusses COVID-19.

        Read More
      Innovate Carolina, 5/11/2020

      What they’re trained for: Biomedical engineers at UNC-Chapel Hill and NC State respond to COVID-19 by teaming to speed the development of an emergency ventilator

      The Carolina Respiratory Emergency – Ventilator (CaRE-Vent) team is advancing knowledge in the biomedical design community about how to create emergency ventilators. Biomedical engineering student Kathlyne Bautista always knew that her coursework and training would set her on a path to make a life-changing difference for people. But before the coronavirus pandemic, she didn’t realize just how soon that opportunity would arrive. 

        Read More
      NCBiotech, 5/8/2020

      RedHill Approved for US COVID-19 Study

      Fresh off a small – but successful – COVID-19 study in Israel, RedHill Biopharma has received approval to test its investigational drug, opaganib, in the United States.

        Read More
      NCBiotech, 5/7/2020

      UNC-CH Ranks Tops Among US Universities in Coronavirus Research

      If you’ve gotten the impression that North Carolina is a hotbed of research and development to combat the COVID-19 coronavirus, you’d be right. Nowhere is that more evident than at the University of North Carolina at Chapel Hill, home to some of the top coronavirus experts in the world and the highest-ranked U.S. university for coronavirus research. 

        Read More
      WRAL TechWire, 5/7/2020

      LabCorp making COVID-19 antibody tests available to individuals

      LabCorp is making its recently launched COVID-19 anti-body test available to individuals. Interested individuals can visit LabCorp.com for more details.

      “With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com,” the company says.

        Read More
      NCBiotech, 5/4/2020

      Grifols To Develop Plasma-Derived Treatment for COVID-19

      Grifols, one of the world’s leading producers of plasma-based medicines, is collecting a blood product from recovered COVID-19 patients to develop a possible treatment for the coronavirus disease.

        Read More
      WRAL TechWire, 5/4/2020

      All hands on deck: COVID-19 engineering response team assembles from every corner at Duke

      At the beginning of 2020, Dr. Alejandro Pino’s attention was focused on designing and patenting feeding tubes that can unclog themselves while also pursuing a pulmonology and critical care fellowship in the Duke University School of Medicine. Just a few months later, a novel coronavirus turned the world upside down, and feeding tubes were no longer Pino’s most pressing project.

        Read More
      WRAL TechWire, 5/4/2020

      Golden LEAF offers another $125M in COVID-19 disaster loans for small businesses

      Golden LEAF, a statewide economic development group, is making another $125 million in loans available to small businesses across North Carolina following the N.C. General Assembly’s passage of a COVID-19 pandemic relief bill that was signed into law Monday by Gov. Roy Cooper.

        Read More
      University of North Carolina System

      The UNC System Contributes to Combating COVID-19

      The UNC System’s response to COVID-19 offers a vivid reminder that higher education is about much more than delivering information. Collectively, our institutions serve North Carolina through instruction, research, and service. The UNC System’s contributions to the state’s efforts to combat this pandemic underscore the long-term value of supporting this mission.

      This page compiles stories about how the UNC System is responding through research, service and driving economic growth.

        Read More
      NCBiotech, 4/30/2020

       Durham’s Chimerix Gets FDA Nod to Test Cancer Drug in COVID-19 Patients

      Chimerix has gotten the green light to test an investigational cancer drug to treat COVID-19 patients. The Durham-based biopharmaceutical company announced it has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2/3 study ofdociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).

        Read More
      News & Observer, 4/29/2020

      ‘A game changer’ — Drug tested in UNC labs shows positive results for COVID-19 treatment

      A treatment that reduces recovery time for patients with COVID-19 showed positive results in clinical trials, UNC-Chapel Hill announced Wednesday. The medication, called remdesivir and originated in the labs at UNC-CH, has been a critical piece of the effort to fight the coronavirus pandemic. On Wednesday, the nation’s coronavirus task force shared the positive results that it accelerates recovery.

        Read More
      NCBiotech, 4/29/20

      Feeling the Heat from COVID-19? Heat Biologics May Have an Answer

      For those feeling the health and economic heat from COVID-19 – and that’s just about everyone – Heat Biologics says it could soon offer up a potential solution. The Morrisville-based clinical-stage biotech company specializes in disease-fighting therapies that activate patients’ immune systems. So it is working on a vaccine that tackles the COVID-19 coronavirus on two fronts.

        Read More
      Contract Pharma, 4/28/2020

      MedPharm Expands Testing Models to Target Coronavirus

      MedPharm has expanded its testing models to support pharmaceutical development programs targeting Coronavirus treatments. These models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial) and deep lung (alveolar) epithelia against members of the Coronaviridae family. 

        Read More
      NCBiotech, 4/28/2020

      LabCorp Expands Reach of COVID-19 Antibody Test

      A LabCorp blood test that helps identify individuals who’ve been exposed to the COVID-19 coronavirus is now broadly available. The Burlington-based life science company, which originally targeted the antibody blood analysis to healthcare workers, now offers it to anyone recommended for testing by a doctor or healthcare provider.

        Read More
      NCBiotech, 4/27/2020

      RedHill Experimental Drug Shows Promise As COVID-19 Treatment

      Finally, a little encouraging news on the COVID-19 coronavirus front. RedHill Biopharma, an Israeli specialty company with U.S. commercial headquarters in Raleigh, reports that all six COVID-19 patients who recently received its investigative drug, opaganib, got better. 

        Read More
      NCBiotech, 4/27/2020

      Duke Gets Grant to Develop ‘Fast, Simple, Low-Cost’ COVID-19 Test

      Duke University biomedical engineers are hoping a rapid testing platform originally designed to detect Ebola can now be used to catch antigens to COVID-19. Now thanks to a $119,000 grant from the National Science Foundation, the team is getting to put it to the test.

        Read More
      NCBiotech, 4/23/2020

      Metabolon Study to Provide Better Understanding of COVID-19

      Why do some patients die from the COVID-19 coronavirus, while others have symptoms so mild they may not even realize they’re sick?  How can treatments for the disease work in some cases, while having no positive effect in others? These are just a couple of the questions Metabolon, a Morrisville-based precision health company, hopes to answer during a year-long COVID-19 study it is conducting with the Institute for Systems Biology (ISB).

        Read More
      NCBiotech, 4/22/20202

      Recovered COVID-19 Patients Can Donate Plasma at UNC, Some Grifols Plasma Centers

      Americans who have recovered from COVID-19 may help save others from the disease by donating their convalescent plasma at the University of North Carolina in Chapel Hill, or at plasma donor sites operated elsewhere around the country by the global biotherapeutics company Grifols.

        Read More
      NCBiotech 4/22/2020

      LabCorp Offers Home Testing Kit for COVID-19

      Healthcare workers and first responders who have symptoms of COVID-19 now can use a LabCorp kit to self-test for the coronavirus at home. The Burlington-based life sciences company has received Emergency Use Authorization (EUA) from the Food and Drug Administration, which allows patients  to collect nose swab specimens with LabCorp’s Pixel COVID-19 kit. It is the first coronavirus diagnostic test authorized by the FDA that has a home collection option.

        Read More
      Triangle Business Journal, 4/21/2020

      Why a North Carolina facility could soon be mass producing a coronavirus treatment

      Grifols (NASDAQ: GRFS), a Spanish pharmaceutical company that calls Johnston County home to its largest manufacturing site, has begun the process of identifying, screening and selecting recovered coronavirus patients to donate plasma. The collected plasma will be used to produce a therapeutic — specifically a hyperimmune globulin — that Grifols hopes will be an effective treatment for the disease.

      Article behind paywall.

        Read More
      NCBiotech, 4/20/2020

      RedHill Pursues Two Potential COVID-19 Treatments

      RedHill Biopharma is another step closer to getting one of its potential treatments for COVID-19 tested.The Israeli company, which has its U.S. headquarters and commercial operations in Raleigh, got the green light to provide its investigational drug, RHB-107 (upamostat, WX-671), for testing in non-clinical studies against the coronavirus.

        Read More
      NCBiotech, 4/20/2020

      NC State Students Make Shields to Protect Medical Workers from COVID-19

      Healthcare workers on the coronavirus frontline continue to risk their own lives to care for the sick. However, a group of graduate student volunteers at North Carolina State University’s Mechanical and Aerospace Engineering Department are determined to protect them.

        Read More
      NCBiotech, 4/10/2020

      BioCryst to Test Anti-Viral Treatment for COVID-19 in Brazil

      Durham-based BioCryst Pharmaceuticals will conduct a clinical trial in Brazil to see if its investigational anti-viral drug is effective in treating the COVID-19 coronavirus. The therapy, galidesivir, will be used in a two-phase study of hospitalized adults who have moderate to severe COVID-19 infections. 

        Read More
      UNC Chapel Hill Research, 4/9/2020

      Open science drug discovery partnership aims to invest $125 million to prevent future pandemics

      On Wednesday, the Structural Genomics Consortium, the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation announced the launch of the Rapidly Emerging Antiviral Drug Development Initiative, a global organization aimed at discovering and developing drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.

        Read More
      NCBiotech, 4/7/2020

      Cellex Cleared to Market Antibody Test for COVID-19

      Cellex, a medical diagnostics company with U.S. headquarters and labs in Research Triangle Park, has launched a new antibody test for detecting COVID-19 infection.The company’s qSARS-COV-2 IgG/IgM Rapid Test is permitted for distribution and use under the public health emergency guidance issued by the U.S. Food and Drug Administration. 

        Read More
      WRAL TechWire, 4/7/2020

      UNC researchers playing key role in development of potential COVID-19 treatment

      Scientists are hopeful that a new drug, called EIDD-2801, could change the way doctors treat COVID-19. The drug shows promise in reducing lung damage, has finished testing in mice and will soon move to human clinical trials.

        Read More
      NCBiotech, 4/6/2020

      Advanced Animal Diagnostics Prepares COVID-19 Test for Humans

      Advanced Animal Diagnostics (AAD) usually makes tests to help farmers monitor the health of their livestock. But in the age of coronavirus, the Research Triangle Park company is pivoting. The young ag tech firm is “repurposing” its QScout blood test platform, which is usually used to detect disease in cattle, to now be used for humans in the fight against COVID-19.

        Read More
      NCBiotech, 4/1/2020

      BioMedomics Teams with BD to Launch Rapid COVID-19 Test

      Morrisville-based BioMedomics, a small diagnostics company supported by the North Carolina Biotechnology Center, has partnered with BD (Becton Dickinson & Co.) to launch its new blood test for COVID-19 that can detect the infection within 15 minutes.

        Read More
      Duke Today, 4/2/2020

      Duke to Lead $50 Million Study of COVID-19 Prevention in Healthcare Workers

      The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine (HCQ) as a preventive drug for the novel coronavirus.

        Read More
      NCBiotech, 4/1/2020

      Brii Biosciences, Chinese Partners Set to Develop COVID-19 Antibodies

      Brii Biosciences, a biopharmaceutical company with a Durham presence, is collaborating with Chinese scientists to discover, develop, manufacture and commercialize monoclonal antibodies to fight COVID-19.

        Read More
      NCBiotech, 3/30/2020

      NC Startup Awaits FDA OK for ‘Low-Cost’ COVID-19 Ventilator

      As the world grapples with a shortage of ventilators for COVID-19 patients, a small North Carolina life science startup has designed a low-cost option. BioMedInnovations (BMI), headquartered outside Charlotte with a research lab in Research Triangle Park, hopes to get federal fast-track approval this week to manufacture and distribute its uniquely simple device to help people breathe.

        Read More
      NCBiotech, 3/30/2020

      Carolina Liquid Chemistries Introduces Tests for COVID-19, Norfentanyl

      Carolina Liquid Chemistries – a Greensboro diagnostics and drug screening company – has introduced two new immunoassays to test for COVID-19 and for norfentanyl, the major metabolite of the synthetic opioid pain reliever fentanyl.

        Read More
      Triangle Business Journal, 3/30/2020

      Novan explores potential COVID-19 treatment, raises $8 million

      A Triangle company that's struggled to develop its lead asset has brought in $8 million through a new public offering as it unveils plans to explore potential applications of its platform in the fight against COVID-19.

      Article behind paywall

      NCBiotech, 3/27/2020

      Q2 Solutions, U of Texas Medical Branch Team Up to Help Find COVID-19 Vaccines

      Q2 Solutions, a clinical trial laboratory services organization headquartered in Morrisville, has teamed up with the University of Texas Medical Branch to develop an assay for analyzing COVID-19 vaccine candidates.

        Read More
      NCBiotech, 3/27/2020

      Grifols Developing Potential Treatments for COVID-19

      Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and test a potential COVID-19 therapy derived from the blood plasma of patients who have recovered from the coronavirus infection.

        Read More
      NCBiotech, 3/27/2020

      NC's Gilero Uses Ingenuity, 3D Printing to Expand COVID-19 Protective Equipment, Ventilators

      Using 3D printers, Morrisville medical device manufacturer Gilero has begun a three-tiered response to the shortage of COVID-19 protective equipment for healthcare workers.

        Read More
      Duke Health, 3/26/2020

      Duke Starts Novel Decontamination of N95 Masks to Help Relieve Shortages

      Facing a critical shortage of N95 face masks that block the coronavirus, Duke Health research and clinical teams have confirmed a way to use existing vaporized hydrogen peroxide methods to decontaminate the masks so they can be reused.

        Read More
      WRAL TechWire, 3/25/20202

      Duke joins first national effort to test potential COVID-19 therapy

      Adults with severe symptoms of the novel illness will have the opportunity to participate in Duke University Hospital’s test of an investigational treatment with an antiviral agent known as remdesivir. Remdesivir is an antiviral agent that was previously tested in humans with Ebola virus disease and has shown promise in animal studies against MERS and SARS, diseases that emerged from different strains of the coronavirus.

        Read More
      NCBiotech, 3/23/2020

      Heat Biologics, University of Miami Developing Quick Point-Of-Care COVID-19 Test

      Heat Biologics, a publicly traded North Carolina biotechnology company, is adding a rapid point-of-care COVID-19 diagnostic test to its product development pipeline. The new test is in addition to the provisional patent application the Morrisville company filed March 3 to apply its immune system activating technology to prevent and/or treat COVID-19. 

        Read More
      NCBiotech, 3/20/2020

      LabCorp Able to Perform 20,000 COVID-19 Tests Per Day 

      LabCorp says it’s ahead of schedule in ramping up its capacity to conduct COVID-19 tests, and is now able to perform more than 20,000 of the tests per day. The Burlington-based company says it has doubled its COVID-19 testing capacity in one week at its labs in North Carolina, Arizona and New Jersey. 

        Read More
      NCBiotech, 3/17/2020

      NCCU Awarded Grant to Help Detect Biological Threats at the Border

      North Carolina Central University has received a $330,000 grant to develop tools that help the U.S. Department of Homeland Security predict and spot risks at the border from biological threats such as COVID-19, African swine fever, and insect pests.

        Read More
      WRAL TechWire, 3/16/20202

      UNC Health deploys coronavirus test

      A coronavirus test developed by Melissa Miller, director of the Clinical Molecular Microbiology Laboratory at the UNC School of Medicine, was being deployed by UNC Health on Monday, officials said. The test should help reduce some of the burden on North Carolina’s public health lab regarding testing, they said.

        Read More
      NCBiotech, 3/13/2020

      Medicago Vaccine Could Help Smoke Out Coronavirus

      An ancient relative of tobacco, much maligned for the damage it has inflicted on public health, is key to a new vaccine to prevent the novel coronavirus. Medicago – a Canadian company with a biomanufacturing facility in Durham –  has used it to produce an experimental plant-based vaccine for COVID-19, the coronavirus disease that has now reached a global pandemic level. 

        Read More
      NCBiotech, 3/12/2020

      BioMedomics Seeks FDA OK for COVID-19 Rapid Diagnostic

      Morrisville-based BioMedomics, a small diagnostics company supported by the North Carolina Biotechnology Center, has developed a new test for rapidly detecting COVID-19, the coronavirus infection that is spreading rapidly throughout the world.

        Read More
      WRAL TechWire, 3/12/2020

      Biotech firm bioMerieux, which has an HQ in Durham, working on 3 coronavirus tests

      France-based bioMerieux, which has a big Triangle connection, is the latest biotech firm developing tests it says will help health officials detect the coronavirus. The company, which focuses on in vitro (test tube) diagnostics, operates its headquarters for the US, Canada and Latin America in Durham.

        Read More
      Triad Business Journal, 3/11/2020

      CDC awards North Carolina $13 million to combat coronavirus

      North Carolina is set to receive more than $13 million from the Centers for Disease Control and Prevention (CDC) as part of a federal initiative to combat the coronavirus pandemic.

        Read More
      WRAL TechWire, 3/11/2020

      LabCorp is performing ‘several thousands’ of coronavirus tests per day to meet surge in demand

      Burlington-based life science conglomerate LabCorp says it is now performing “several thousands” of coronavirus tests per day in the wake of an increasing number of new coronavirus infections in the United States. Meanwhile, it is rapidly adding new equipment and staff to create additional capacity for patients who should be tested across the country.

        Read More
      News & Observer, 3/10/2020

      NC governor declares state of emergency as state deals with coronavirus

      North Carolina Gov. Roy Cooper declared a state of emergency Tuesday as leaders continue to deal with the coronavirus outbreak. The state now has 7 people who have tested positive for COVID-19, the disease caused by the coronavirus, health officials said.

        Read More
      Triangle Business Journal, 3/10/2020

      For Duke researchers – 'Every virus has an Achilles' heel'

      As the novel coronavirus continues to spread across the globe, researchers are racing to create a vaccine to eradicate it, including those at Duke University who have spent decades – funded by billions of dollars– studying vaccine development for some of the world's most pressing diseases.

      Article behind paywall.

        Read More
      Duke Today, 3/10/20

      What We've Learned About Coronavirus: Infectious disease experts on the spread, the science and the scenarios for the virus

      Three Duke infectious disease experts talked with the media Tuesday to discuss the origins and spread of COVID-19 and the global and U.S. response. Duke plans a series of briefings on the way the novel coronavirus is affecting the world.

      Keep reading for highlights from the briefing.

        Read More
      News and Observer, 3/7/2020

      An air-locked lab at UNC is leading research on cures for the coronavirus

      For scientists working in laboratories across the world, their names usually won’t become well known outside of the subsection of people reading academic journals. But the outbreak of COVID-19 — the disease caused by the novel coronavirus that has spread from China around the globe this year — has pushed researchers at UNC-Chapel Hill, specifically Dr. Ralph Baric, into the spotlight.

        Read More
      WRAL TechWire, 3/5/2020

      RTP firm BioMedomics says it has ‘quick and easy’ coronavirus test

      BioMedomics, a medical diagnostic company based in RTP, says it has developed a novel coronavirus test that can turn around results in less than 15 minutes, potentially offering a fix to the current testing backlog.

        Read More
      NCBiotech, 3/5/2020

      LabCorp Launches New Test for Coronavirus

      Burlington-based life science conglomerate LabCorp is the latest company to provide a test for COVID-19. This coronavirus has gained a foothold in more than 84 countries so far as it continues its unrelenting march across the globe.

       

        Read More
      NCBiotech, 3/4/2020

      NC Researchers, Companies Help Lead Coronavirus Battle

      The rapid global march of the coronavirus that began in Wuhan, China several months ago could be slowed by researchers and biotech firms 7,770 miles away – in the Research Triangle of North Carolina.

        Read More
      WRAL TechWire, 3/3/2020

      Morrisville-based Heat Biologics joins global effort to discover coronavirus vaccine

      The Morrisville-based biotechnology company announced today that it has formally launched a program within its wholly-owned subsidiary, Zolovax, Inc., to develop a vaccine using its immune activating gp96 vaccine platform for treating or preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19.

        Read More

      North Carolina COVID-19 News

      NCBiotech, 3/12/2020

      BioMedomics Seeks FDA OK for COVID-19 Rapid Diagnostic

      Morrisville-based BioMedomics, a small diagnostics company supported by the North Carolina Biotechnology Center, has developed a new test for rapidly detecting COVID-19, the coronavirus infection that is spreading rapidly throughout the world.

      Read more
      WRAL TechWire, 3/12/2020

      Biotech firm bioMerieux, which has an HQ in Durham, working on 3 coronavirus tests

      France-based bioMerieux, which has a big Triangle connection, is the latest biotech firm developing tests it says will help health officials detect the coronavirus. The company, which focuses on in vitro (test tube) diagnostics, operates its headquarters for the US, Canada and Latin America in Durham.

      Read more
      Triad Business Journal, 3/11/2020

      CDC awards North Carolina $13 million to combat coronavirus

      North Carolina is set to receive more than $13 million from the Centers for Disease Control and Prevention (CDC) as part of a federal initiative to combat the coronavirus pandemic.

      Read more
      WRAL TechWire, 3/11/2020

      LabCorp is performing ‘several thousands’ of coronavirus tests per day to meet surge in demand

      Burlington-based life science conglomerate LabCorp says it is now performing “several thousands” of coronavirus tests per day in the wake of an increasing number of new coronavirus infections in the United States. Meanwhile, it is rapidly adding new equipment and staff to create additional capacity for patients who should be tested across the country.

      Read more
      News & Observer, 3/10/2020

      NC governor declares state of emergency as state deals with coronavirus

      North Carolina Gov. Roy Cooper declared a state of emergency Tuesday as leaders continue to deal with the coronavirus outbreak. The state now has 7 people who have tested positive for COVID-19, the disease caused by the coronavirus, health officials said.

      Read more
      Triangle Business Journal, 3/10/2020

      For Duke researchers – 'Every virus has an Achilles' heel'

      As the novel coronavirus continues to spread across the globe, researchers are racing to create a vaccine to eradicate it, including those at Duke University who have spent decades – funded by billions of dollars– studying vaccine development for some of the world's most pressing diseases.

      Article behind paywall.

      Read more
      DUKE TODAY, 3/10/2020

      What We've Learned About Coronavirus: Infectious disease experts on the spread, the science and the scenarios for the virus

      Three Duke infectious disease experts talked with the media Tuesday to discuss the origins and spread of COVID-19 and the global and U.S. response. Duke plans a series of briefings on the way the novel coronavirus is affecting the world.

      Keep reading for highlights from the briefing.

      Read more
      NEWS AND OBSERVER, 3/7/2020

      An air-locked lab at UNC is leading research on cures for the coronavirus

      For scientists working in laboratories across the world, their names usually won’t become well known outside of the subsection of people reading academic journals. But the outbreak of COVID-19 — the disease caused by the novel coronavirus that has spread from China around the globe this year — has pushed researchers at UNC-Chapel Hill, specifically Dr. Ralph Baric, into the spotlight.

      Read more
      WRAL TECHWIRE, 3/5/2020

      RTP firm BioMedomics says it has ‘quick and easy’ coronavirus test

      BioMedomics, a medical diagnostic company based in RTP, says it has developed a novel coronavirus test that can turn around results in less than 15 minutes, potentially offering a fix to the current testing backlog.

      Read more
      ncbiotech, 3/5/2020

      LabCorp Launches New Test for Coronavirus

      Burlington-based life science conglomerate LabCorp is the latest company to provide a test for COVID-19. This coronavirus has gained a foothold in more than 84 countries so far as it continues its unrelenting march across the globe.

      Read more

      Pagination

      • Current page 1
      • Page 2
      • Next page Next ›
      • Last page Last »
      Our 35th Anniversary

      Footer Menu

      • About
        • Transforming Life Science
        • Leadership Team
        • Board of Directors
        • Image Gallery
      • Donate
      • News
      • Events
      • Jobs Board
      Contact us
      919.541.9366 Call NCBiotech
      Newsletter Sign Up Newsletter
      More Contact Info » More contact info »

      © 2021

      North Carolina Biotechnology Center. All rights reserved. Website Design by Trone Brand Energy

      Copyright Menu

      • Privacy
      • Legal